- Mallinckrodt receives FDA approval for Xartemis XR
- Ensuring access to chronic pain medications
- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- Gina Libby strives to improve pain medication legislation
- Chronic pain sufferer Dennis Kinch pens book to encourage pain community
CHADDS FORD, Pa. The Food and Drug Administration has granted priority review to an opioid painkiller designed to thwart drug abusers.
Endo Pharmaceuticals said Wednesday that the FDA would expedite review of its new oral formulation of long-acting oxymorphone, which is designed to be crush-resistant. The FDA expects to take action on the drug in early January.
The drug is designed to treat moderate to severe chronic pain in patients requiring around-the-clock treatment for a long period of time. It is a tablet designed to resist crushing, breaking, powdering or pulverizing.